Kopin Receives $1.1M Second Production Order For Specialized Weapon Sight Module

Kopin Corporation (NASDAQ:KOPN), a leading developer and provider of high-resolution microdisplays and application-specific optical subassemblies for defense, enterprise, consumer and medical products, today announced it

Kopin Corporation (NASDAQ:KOPN), a leading developer and provider of high-resolution microdisplays and application-specific optical subassemblies for defense, enterprise, consumer and medical products, today announced it has received a $1.1 million follow-on production order for an application-specific, long range optical weapon sight module.

“Kopin continues to be a leader in weapon sight eyepieces for soldiers, and this order is an example of our microdisplays and optical subassemblies being used in the most rugged environments around the world,” said Bill Maffucci, Kopin’s Sr. Vice President of Business Development and Strategy. “This follow-on order is for one of Kopin’s specialized weapon sight eyepieces. We believe the situation in Europe and continued elevated defense spending will provide significant opportunities for follow-on orders.”

This weapon sight module offers a sophisticated video “see through” augmented reality capability that gives soldiers critical information with clear, bright symbology in their weapons sights. It incorporates our proprietary CyberDisplay® and our custom-designed optics, which have been proven as the reliable and high-performing core in more than 250,000 weapon sight systems.

Total
0
Shares
Related Posts
Read More

Sorrento Reports Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept; Says Achieving Improvements In Rheumatoid Arthritis Disease Measures At 50% Of Standard Dose For Patients (7 of 7) With Inadequate Response To Subcuta

Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements

SRNE